Why Are Apple Inc. (AAPL) Shares Sinking?

Page 1 of 2

As of this writing, shares of Apple Inc. (NASDAQ:AAPL) have fallen close to 4% in late morning trading, and did hit as low as $545 an hour and a half after the opening bell. The obvious question for investors is: why are shares of the tech giant slipping? After all, with talk of a special dividend (see Will Apple Pay a Special Dividend?), growing market share in its smartphone segment, and ongoing snippets about the iOS’s domination of online browsing (see Apple Products Make Up the ‘Bulk’ of Mobile Traffic), there have been many qualitative reasons to be bullish about Apple lately. Don’t even get us started on the stock’s bargain bin valuation either; in the mind of a pure value investor, it’s hard not to be attracted to a 9.9X forward P/E and a sub-1.0 PEG ratio.

Apple Inc. (AAPL)Well, here’s one piece of negative news that may have driven shares of AAPL down, according to Reuters. Research consultancy firm IDC released its latest tablet forecast today, and it concludes that Apple Inc. (NASDAQ:AAPL) is seeing increased competition from Android in this arena. Originally reported on the LA Times, “Android-based tablets continue to gain momentum […] market share for Android tablets [is expected to] rise from 39.8% in 2011 to 42.7% in 2012. Apple is expected to see its market share for tablets decline, from 56.3% to 53.8%.” Moreover, Ryan Reith of IDC had this to say:

“The breadth and depth of Android has taken full effect on the tablet market as it has for the smartphone space […] Android tablet shipments will certainly act as the catalyst for growth in the low-cost segment in emerging markets given the platform’s low barrier to entry on manufacturing. At the same time, top-tier companies like Samsung, Lenovo, and ASUS are all launching Android tablets with comparable to premium products, but offered at much lower price points.”

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!